WORLD MEDICAL INNOVATION FORUMSM

CANCER | APRIL 25–27, 2016

The World Medical Innovation Forum is a global

gathering of more than 1,200 senior health care

leaders hosted by Partners HealthCare in the

heart of Boston. It was established to respond to

the intensifying transformation of health care and

its impact on innovation. The Forum is rooted in

the belief that no matter the magnitude of that

change, the center of health care needs to be a

shared, fundamental commitment to collaborative

innovation – industry and academia working

together to improve patient lives.

The 2016 World Medical Innovation Forum will

feature the newest technologies to diagnose, treat

and manage cancer.

World MedicalInnovation Forum

P A R T N E R S H E A L T H C A R E

Headquartered in Boston,

Massachusetts, Partners HealthCare

is one of the nation's most highly

regarded hospital systems. Its

founding institutions, Brigham and

Women’s Hospital and Massachusetts

General Hospital, are staffed by

Harvard Medical School faculty

and have a legacy of innovation

that includes 18 Nobel Laureates

and therapies that have redefined

the contemporary standard of care.

It's the largest academic research

enterprise in the nation at more

than $1.5 billion of annual research.

Its staff is responsible for hundreds

of products and best practices

that benefit millions of patients

worldwide.

CANCER | April 25–27, 2016

CARDIOVASCULAR | May 1–3, 2017

Keynoters

Joseph JimenezCEO, Novartis

Robert BradwayCEO, Amgen

Robert MulroyCEO, Merrimack Pharmaceuticals

Briggs Morrison, MDCEO, Syndax Pharmaceuticals

David LeeCEO, Lumicell

Marc de GaridelCEO, Ipsen

Paul HudsonPresident, AstraZeneca US,Executive Vice President,AstraZeneca North America

David Torchiana, MDCEO, Partners HealthCare

Daniel Haber MD, PhDDirector, Massachusetts General Hospital Cancer Center, Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology,Harvard Medical School

Glenn Dranoff , MDGlobal Head of Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research

Christopher ViehbacherManaging Partner, Gurnet Point Capital

Henri TermeerJean-François Formela, MDPartner, Atlas Venture

Bob Tepper, MDPartner, Third Rock Ventures

Kathy GiustiFounder and Executive Chairman, MMRF

Giovanni Caforio, MDCEO, Bristol-Myers Squibb

Richard GonzalezCEO, AbbVie

Michael Pellini, MDCEO, Foundation Medicine

David Schenkein, MDCEO, Agios Pharmaceuticals

Bruno StriginiPresident, Novartis Oncology

William Hait, MD, PhDGlobal Head, Janssen R&D, J&J

Gary ReedyCEO, American Cancer Society

Thomas Lynch, MDCEO, Mass GeneralPhysician’s Organization

Monica Bertagnolli, MDChief, Division of Surgical Oncology,Brigham and Women’s Hospital,Professor of Surgery,Harvard Medical School

Judy Salerno, MDCEO, Susan G. Komen for the Cure

William Sellers, MDVice President and Global Head of Oncology, Novartis Institutes for BioMedical Research

Nancy Snyderman, MDMedical Advisor,GE Healthymagination

Amir Nashat, PhDManaging Partner, Polaris Partners

Jim RobinsonPresident, Astellas Pharma US

Francis Cuss, MDExecutive Vice President andChief Scientifi c Offi cer, R&D,Bristol-Myers Squibb

Every Speaker an Expert. Every Panel Unique.Every Seat Invaluable.Featured speakers include more than 100 CEOs, top cancer innovators, leading investors, and national journalists.

A War or Moonshot: Where Do We Stand?

Arms Race in Radiation

Breakthrough Devices to Treat Cancer

Building and Managing a Disruptive Cancer Pipeline

Cancer Diagnostics: New Uses, New Reimbursements?

Combination Cancer Therapies: Drug Resistanceand Therapeutic Index

Curative Therapies: Game Changing Scienceand its New Economics

Discovery Cafe: Top Faculty Share Their Work

Disruptive Dozen

Early Detection and Prevention of Cancer

Epigenetics and Novel Cancer Targets

First Look: The Next Wave of Cancer Breakthroughs

Funding the Next Cancer Companies

Global Economics of Cancer: Markets in Transition

Immunotherapy I: Checkpoint Activation and Cancer Vaccines

Immunotherapy II: Cell Based Therapies

New Philanthropy: Patients Driving Innovation

Study Designs to Meet the Challengesof Personalized Cancer Medicines

Successful Portfolio Strategy

Surviving Cancer: New Realities, New Needs

Sponsors

P R E S E N T I N G

C O L L A B O R A T O R S

MON. APRIL 25, 20168:00 AM - 8:00 PM

TUES. APRIL 26, 20168:15 AM - 6:45 PM

WED. APRIL 27, 20168:10 AM - 1:20 PM

Panels

S T A K E H O L D E R

S T R A T E G I C

Breakthrough Technologies

FIRST LOOKThe Next Wave of Cancer BreakthroughsMonday Morning | 8AM – 12PMPlease join us as some of our most creative investigators describe their most promising commercially related research. Rapid-fire presentations by two dozen early-career Harvard Medical School faculty will highlight compelling new discoveries and insights that will be the cancer care products of the future. If identifying new high impact cancer technology is your passion—as an investor, company leader, donor, entrepreneur or investigator—this session is for you. These young stars from Brigham and Women's Hospital, Massachusetts General Hospital and Dana-Farber Cancer Institute will each describe their work in highly organized 10-minute sessions.

SpeakersAll speakers are affiliated with Harvard Medical SchoolCyril Benes, PhD, MGHPriscilla Brastianos, MD, MGHMark Cobbold, MD, PhD, MGHRyan Corcoran, MD, PhD, MGHShawn Demehri, MD, PhD, MGHDaniela Dinulescu, PhD, BWHRitu Gill, MD, BWHWilhelm Haas, PhD, MGHLida Hariri, MD, PhD, MGHAditi Hazra, PhD, BWHJayender Jagadeesan, PhD, BWHHakho Lee, PhD, MGHAlexander Lin, PhD, BWHSandra McAllister, PhD, BWHMikael Pittet, PhD, MGHMiguel Rivera, MD, MGHSandro Santagata, MD, PhD, BWHShiladitya Sengupta, PhD, BWHPaul Shyn, MD, BWHMatthew Steinhauser, MD, BWHShannon Stott, PhD, MGHMario Suva, MD, PhD, MGHDavid Ting, MD, MGH

DISCOVERY C AFÉ LUNCHEnjoy Lunch with Top Cancer Leadershipfrom across Partners HealthCare Monday Lunch | 12PM – 1:30PMTop faculty from Brigham and Women's Hospital, Massachusetts General Hospital and Dana-Farber Cancer Institute will host intimate lunch discussions on developments in their field and their own research. Forum attendees are invited to engage with these internationally renowned leaders on topics ranging from the integration of specific oncology therapies to the newest diagnostic methods. This will be an exciting and energized session with abundant opportunities for direct exchanges with these world leaders. Open registration for tables by topic/speaker (8 guests per table) is available as part of World Forum registration.

SpeakersAll speakers are affiliated with Harvard Medical SchoolKenneth Anderson, MD, BWHMonica Bertagnolli, MD, BWHJoan Brugge, PhD, HMSGeorge Demetri, MD,Dana-Farber Don Dizon, MD, MGHDavid Fisher, MD, PhD, MGHKeith Flaherty, MD, MGHLevi Garraway, MD, PhD,Dana-FarberJeffrey Golden MD, BWHDaniel Haber, MD, PhD, MGHElizabeth Henske, MD, BWH,Dana-FarberTheodore Hong, MD, MGHJohn Iafrate, MD, MGHKatherine Janeway, MD,Dana-FarberKeith Joung, MD, PhD, MGHCigall Kadoch, PhD,Dana-Farber

Jeannie Lee, MD, PhD, MGHMaximo Loda, MD, BWHJay Loeffler, MD, MGHRobert Martuza, MD, MGHMarcela Maus, MD, PhD, MGHAnn Partridge, MD,Dana-FarberScott Rodig, MD, PhD, BWHDeborah Schrag, MD, BWH, Dana-FarberArlene Sharpe, MD, PhD, BWH, Dana-FarberJulie Silver, MD, SpauldingKimberly Stegmaier, MD,Dana-FarberGuillermo Tearney, MD, MGHRalph Weissleder, MD, PhD, MGHJonathan Whetstine, PhD, MGH

Kenneth Anderson, MDDirector, Jerome Lipper Multiple Myeloma Center, Kraft Family Professor of Medicine,Harvard Medical SchoolUsman Azam, MDGlobal Head, Cell & Gene TherapiesUnit, NovartisMonica Bertagnolli, MDChief, Division of Surgical Oncology,Brigham and Women's Hospital,Professor of Surgery,Harvard Medical SchoolJames Bradner, MDPresident, Novartis Institutesfor BioMedical ResearchRobert BradwayCEO, AmgenTroy Brennan, MDEVP and CMO, CVS HealthJoan Brugge, PhDProfessor, Director, Ludwig Center,Harvard Medical SchoolGiovanni Caforio, MDCEO, Bristol-Myers SquibbBruce Chabner, MDCancer Center Clinical DirectorEmeritus, Massachusetts GeneralHospital, Professor, Department ofMedicine, Harvard Medical SchoolAndy Chan, MDProgram Director, GastroenterologyTraining Program, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical SchoolAntonio Chiocca, MD, PhDChairman, Neurosurgery, Brigham and Women's Hospital Professor of Surgery, Harvard Medical SchoolRobert Copeland, PhDPresident of Research andChief Scientific Officer, EpizymeNewt CrenshawVice President of North AmericaOncology, Eli LillyFrancis Cuss, MDExecutive Vice Presidentand Chief Scientific Officer, R&D,Bristol-Myers SquibbThomas Daniel, MDChairman, Celgene ResearchMarc de GaridelCEO, IpsenLouis DeGennaro, PhDCEO, The Leukemia& Lymphoma SocietyGeorge Demetri, MDDirector, Center for Sarcoma and BoneOncology, Senior Vice President forExperimental Therapeutics, Institute Physician, Dana-Farber Cancer Institute

Sheila DharmarajanHead of Business Development,Zelnick Media CapitalKeith Dionne, PhDCEO, Constellation PharmaceuticalsDon Dizon, MDClinical Co-Director, GynecologicOncology, Massachusetts GeneralHospital, Associate Professor ofMedicine, Harvard Medical SchoolGlenn Dranoff, MDGlobal Head of Exploratory Immuno-Oncology, Novartis Institutes forBiomedical ResearchJens Eckstein, PhDPresident, SR OneHelmy Eltoukhy, PhDCEO, Guardant HealthJeffrey Engelman, MD, PhDDirector, Thoracic Oncology and Director, Molecular Therapeutics, Medical Oncology, Massachusetts General Hospital, Laurel Schwartz Associate Professor of Medicine, Harvard Medical SchoolMaurice Ferre, MDCEO, InsightecTim Ferris, MDSenior Vice President of Population Health Management, Partners HealthCareDavid Fisher, MD, PhDChief, Dermatology,Massachusetts General Hospital, Edward Wigglesworth Professor of Dermatology, Harvard Medical SchoolKeith Flaherty, MDDirector, Clinical Research, CancerCenter, Massachusetts GeneralHospital, Associate Professor ofMedicine, Harvard Medical SchoolPat Fortune, PhDSenior Market Sector Leader,Partners InnovationJean-François Formela, MDPartner, Atlas VenturesJamie Freedman, MD, PhDSenior Vice President, Global ClinicalDevelopment MedImmuneMark Frohlich, MDEVP, Development and Portfolio Strategy, Juno TherapeuticsLevi Garraway, MD, PhDDirector, Center for Cancer PrecisionMedicine, Assistant Professor of Medicine, Medical Oncology Service, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical SchoolKathy GiustiFounder and Executive Chairman, MMRF

Jeffrey Golden, MDChair of Pathology, Brigham and Women's Hospital, Ramzi S. Cotran Professor of Pathology, Harvard Medical SchoolRichard GonzalezCEO, AbbVieMarc Grodman, MDCEO, BioReference LaboratoriesDaphne Haas-Kogan, MDChair, Department of Radiation Oncology, Dana-Farber Cancer Institute,Professor of Radiation Oncology,Harvard Medical SchoolDaniel Haber, MD, PhDDirector, Massachusetts General Hospital Cancer Center, Kurt J.Isselbacher/Peter D. Schwartz Professor of Oncology, Harvard Medical SchoolNir Hacohen, PhDImmunologist, Center for Immunologyand Inflammatory Diseases, Massachusetts General Hospital Associate Professor, Medicine, Harvard Medical SchoolWilliam Hait, MD, PhDGlobal Head, Janssen R&D, J&JSean Harper, MDExecutive Vice President,Research and Development, AmgenStephen Hodi, MDDirector, Melanoma Center, Director,Center for Immuno-Oncology,Dana-Farber Cancer Institute,Associate Professor of Medicine,Harvard Medical SchoolTheodore Hong, MDDirector, Gastrointestinal RadiationOncology, Massachusetts GeneralHospital, Associate Professor of Radiation Oncology, Harvard Medical SchoolPaul HudsonPresident, AstraZeneca US,Executive Vice President,AstraZeneca North AmericaJohn Iafrate, MD, PhDAssociate in Pathology, Medical Director, Center for Integrated Diagnostics, Massachusetts General Hospital,Associate Professor of Pathology,Harvard Medical SchoolJoseph JachinowskiCEO, Mevion Medical SystemsKatherine Janeway, MDAssociate Physician, Dana-FarberCancer Institute, Assistant Professor,Harvard Medical SchoolJoseph JimenezCEO, Novartis

Featured Speakers

Keith Joung, MD, PhDAssociate Chief of Pathology for Research, Associate Pathologist, Massachusetts General Hospital, Associate Professor of Pathology, Harvard Medical SchoolCigall Kadoch, PhDPrincipal Investigator, Pediatric Oncology, Dana-Farber Cancer Institute,Assistant Professor, Pediatrics,Harvard Medical SchoolAnne Klibanski, MDChief Academic Officer,Partners HealthCare, Laurie Carrol Guthart Professor of Medicine,Harvard Medical SchoolMaria Koehler, MD, PhDVice President, Oncology Strategy,Innovation and Collaborators,Pfizer OncologyKrishna KumarCEO, Emerging Business, PhillipsPeter Lebowitz, MD, PhDGlobal Therapeutic Area Head,Oncology, Janssen R&DDavid LeeCEO, LumicellJeannie Lee, MD, PhDProfessor of Genetics,Massachusetts General HospitalJonathan LeffPartner, Deerfield InvestmentsGillian Leng, MDDeputy Chief Executive and Director of Health and Social Care, NICENick LeschlyCEO, Bluebird BioNeal Lindeman, MDAssociate Pathologist, Pathology,Brigham and Women's Hospital,Associate Professor, Pathology,Harvard Medical SchoolMassimo Loda, MDSenior Pathologist, Principal Investigator, Brigham and Women's Hospital,Dana-Farber Cancer Institute, Professor, Department of Pathology,Harvard Medical SchoolJay Loeffler, MDChair, Radiation Oncology, Massachusetts General Hospital, Herman and Joan SuitProfessor of Radiation Oncology,Harvard Medical SchoolDavid Louis, MDPathologist-in-Chief, MassachusettsGeneral Hospital, Benjamin CastlemanProfessor of Pathology,Harvard Medical SchoolThomas Lynch, MDCEO, Mass GeneralPhysician's OrganizationMarcela Maus, MD, PhDDirector of Cellular Immunotherapy,Massachusetts General Hospital, Assistant Professor, Harvard Medical School

Briggs Morrison, MDCEO, Syndax PharmaceuticalsRobert MulroyCEO, Merrimack PharmaceuticalsBetsy Nabel, MDPresident, Brigham and Women'sHospital, Professor of Medicine,Harvard Medical SchoolAmir Nashat, PhDManaging Partner, Polaris PartnersAnn Partridge, MDDirector, Adult Survivorship Program,Program for Young Women with Breast Cancer, Dana-Farber Cancer Institute, Associate Professor of Medicine,Harvard Medical SchoolMichael Pellini, MDCEO, Foundation MedicineAmy Pollack, MDVice President, Medical Affairs, CMO,Surgical Businesses and DevelopedMarkets, CovidienGary ReedyCEO, American Cancer SocietyDavid Reese, MDSenior Vice President,Translational Sciences, AmgenAlessandro Riva, MDGlobal Head, Oncology Development and Medical Affairs, Novartis OncologyJames RobinsonPresident, Astellas Pharma USScott Rodig, MD, PhDAssociate Professor,Brigham and Women's HospitalPhil Rowlands, PhDInterim Head, Oncology,Therapeutic Area Unit, TakedaJudy Salerno, MDCEO, Susan G. Komen for the CureDavid Schenkein, MDCEO, Agios PharmaceuticalsDeborah Schrag, MDChief, Division of Population Sciences,Medical Oncology, Dana-Farber Cancer Institute Professor, Medicine,Harvard Medical SchoolWilliam Sellers, MDVice President and Global Head ofOncology, Novartis Institutes forBioMedical ResearchArlene Sharpe, MD, PhDLeader, Cancer Immunology Brigham and Women's Hospital, Dana-Farber Cancer Institute, George Fabyan Professor of Comparative Pathology,Harvard Medical SchoolJulie Silver, MDAssociate Professor, Associate Chair,Strategic Initiatives, Department ofPhysical Medicine and Rehabilitation,Harvard Medical School

Nancy Simonian, MDCEO, Syros PharmaceuticalsPeter Slavin, MDPresident, Massachusetts GeneralHospital, Professor of Healthcare Policy, Harvard Medical SchoolNancy Snyderman, MDMedical Advisor,GE HealthymaginationRisa Stack, PhDGeneral Manager, New Business Creation, GE VenturesBilly StarrFounder & Executive Director,Pan-Mass ChallengeKimberly Stegmaier, MDAssociate Professor, Dana-Farber Cancer Institute, Harvard Medical SchoolBruno StriginiPresident, Novartis OncologyGuillermo Tearney, MD, PhDPathologist, Massachusetts GeneralHospital, Professor of Pathology,Harvard Medical SchoolRobert Tepper, MDPartner, Third Rock Ventures, AdjunctProfessor, Harvard Medical SchoolHenri TermeerClaire ThomSenior Vice President, Global Oncology Development, AstellasMeg TirrellBiotech and Pharma Reporter, CNBCDavid Torchiana, MDCEO, Partners HealthCareMike Vasconcelles, MDCMO, Unum TherapeuticsChristopher ViehbacherManaging Partner,Gurnet Point CapitalRalph Weissleder, MD, PhDDirector, Center for Systems Biology,Massachusetts General Hospital,Professor, Radiology and SystemsBiology, Harvard Medical SchoolJohnathan Whetstine, PhDTepper Family Research Scholar,Massachusetts General Hospital,Associate Professor of Medicine,Harvard Medical SchoolChuck Wilson, PhDCEO, Unum TherapeuticsDow WilsonCEO, Varian Medical Systems

Note: Speakers subject to change.

Join Us for the 2016 World Medical Innovation Forum

Experience the state-of-the-art in cancer technology, care, and research

Understand the prospects for innovation in a transformed health care industry

See firsthand the breakthrough cancer technologies from across the industry

Forge relationships and exchange information with world-recognized clinicians, investors, entrepreneurs, scientists, CEOs, executives, government leaders, philanthropists, and journalists

215 First Street, Suite 500 | Cambridge, MA 02142

worldmedicalinnovation.org

BROUGHT TO YOU BY: